Tetanus

01Pathophysiology

Clostridium tetani is an obligate anaerobic organism found ubiquitously in soil, dust, and animal feces. Its spores are extremely hardy and can survive harsh environmental conditions for years. When spores are introduced into a wound with a low oxygen environment (deep puncture wounds, devitalized tissue, crush injuries, burns), they germinate into vegetative bacteria and begin producing two exotoxins: tetanolysin (of minor clinical significance) and tetanospasmin (the toxin responsible for clinical disease).

Tetanospasmin is the second most potent biological toxin known (after botulinum toxin). Once produced locally at the wound site, the toxin enters the peripheral motor nerve terminals and travels via retrograde axonal transport to the central nervous system, specifically to the presynaptic terminals of inhibitory interneurons in the spinal cord and brainstem. There, it cleaves VAMP/synaptobrevin, a protein essential for synaptic vesicle fusion. This irreversibly blocks the release of the inhibitory neurotransmitters GABA (gamma-aminobutyric acid) and glycine.

The clinical consequence of this blockade is straightforward: without inhibitory input, alpha motor neurons fire unopposed. This produces the hallmark features of sustained involuntary muscle contraction (rigidity) and reflex spasms triggered by even minor sensory stimuli such as noise, light, or touch. The descending pattern of involvement (face and jaw first, then trunk, then extremities) reflects the shorter axonal distance that toxin must travel to reach the brainstem compared with the spinal cord.

Autonomic dysfunction occurs because tetanospasmin also affects the sympathetic nervous system, causing catecholamine surges that manifest as labile hypertension, tachycardia, diaphoresis, and arrhythmias. In severe cases, autonomic instability becomes the leading cause of death, surpassing respiratory failure.

A critical teaching point: once toxin binds to neural tissue, it is irreversible. Recovery requires the growth of new nerve terminals, which explains the prolonged clinical course (weeks to months). This is why passive immunization with TIG must be administered early, before circulating toxin binds, because TIG can only neutralize unbound toxin.

02Classification and Clinical Manifestation

Clinical Forms of Tetanus

Severity Classification (Ablett Classification for Generalized Tetanus)

The incubation period (time from wound to first symptom) ranges from 3 to 21 days, with an average of approximately 8 days. A shorter incubation period correlates with more severe disease and worse prognosis.

The period of onset (time from first symptom to first generalized spasm) is another prognostic marker. A period of onset less than 48 hours predicts severe disease.

The classic clinical progression in generalized tetanus follows a descending pattern: trismus appears first (due to short neural pathway to the brainstem), followed by neck stiffness, dysphagia, abdominal rigidity ("board-like abdomen"), and finally limb rigidity and generalized spasms. Opisthotonus (severe hyperextension of the back) results from the paraspinal muscles, which are stronger than the abdominal flexors, overpowering their counterparts.

03Diagnostic Workup

Tetanus is fundamentally a clinical diagnosis. There is no laboratory test that confirms active tetanus. This is a high-yield concept: vignettes will present a classic clinical picture and test whether you recognize the diagnosis based on history and physical exam alone, or whether you waste time and resources ordering unnecessary confirmatory tests.

The spatula test is a practical bedside maneuver worth knowing. In a normal patient, touching the oropharynx with a spatula or tongue depressor triggers a gag reflex that pushes the spatula out. In a patient with tetanus, the same stimulus triggers a reflex spasm of the masseters, and the patient bites down on the spatula involuntarily. This test has been validated with very high accuracy.

Wound cultures for C. tetani are ordered but have poor sensitivity. A positive culture in the correct clinical context is supportive, but most cases of confirmed tetanus have negative wound cultures. You should never delay treatment while awaiting culture results.

Serum antitoxin levels are useful in retrospect or for epidemiologic purposes. A protective antitoxin level ($\ge \backslash geq$ 0.01 IU/mL) makes clinical tetanus unlikely but does not completely exclude it in rare cases. This test is more helpful for confirming susceptibility rather than confirming disease.

The workup should also include labs to monitor for complications: creatine kinase (rhabdomyolysis from prolonged spasm), renal function, and electrolytes. An arterial blood gas is important in patients with respiratory compromise.

04Management and Treatment

Step 1: Neutralize circulating toxin with Human TIG. This is the most time-sensitive intervention. TIG can only neutralize unbound toxin still circulating in the blood and tissue. Once tetanospasmin has bound to nerve terminals, TIG is ineffective. The dose for established tetanus is 3,000 to 6,000 IU given intramuscularly as a single dose. Some protocols advocate infiltrating a portion of the dose around the wound site. For neonatal tetanus, the dose is 500 IU IM. Administer TIG at a site anatomically distant from the Td/Tdap vaccine to avoid interference.

Step 2: Antibiotic therapy with Metronidazole. Metronidazole 500 mg IV every 6 to 8 hours for 7 to 10 days is the preferred antibiotic. It is chosen over penicillin for a testable reason: penicillin is a GABA antagonist, and since the pathophysiology of tetanus already involves loss of GABAergic inhibition, penicillin could theoretically exacerbate spasms. If metronidazole is unavailable, penicillin G 2-4 million units IV every 4-6 hours is an acceptable alternative, but it is second-line.

Step 3: Wound debridement. Thorough surgical debridement should be performed after TIG has been given (to neutralize any toxin released during manipulation). Removing necrotic tissue eliminates the anaerobic environment necessary for C. tetani to thrive and produce toxin.

Step 4: Spasm control with benzodiazepines. Diazepam is the traditional first-line agent because it directly enhances GABA-A receptor activity, counteracting the loss of inhibitory neurotransmission. Dosing is titrated to clinical effect. In severe cases requiring continuous sedation, a midazolam infusion is often used. For refractory spasms, neuromuscular blockade with a nondepolarizing agent (such as vecuronium or pancuronium) along with mechanical ventilation may be necessary.

Step 5: Active immunization. A critically tested concept: tetanus does not produce natural immunity. Even patients who survive the disease must receive the complete Td/Tdap vaccination series. The toxin is so potent that the amount causing disease is too small to generate an adequate antibody response. Administer the first dose during the acute illness, at a different anatomical site from TIG.

Step 6: Management of autonomic dysfunction. In Grade III-IV disease, autonomic instability is the leading cause of death. IV magnesium sulfate (loading dose 5 g, then 2-3 g/hour infusion, targeting serum levels of 2-4 mmol/L) has become a cornerstone of treatment. It reduces catecholamine release and has concurrent antispasmodic effects. Labetalol is used for combined alpha- and beta-adrenergic blockade. Avoid using pure beta-blockers (such as propranolol) in isolation, as unopposed alpha-adrenergic activity can worsen hypertensive crises. Morphine infusion can help with both pain and sympathetic modulation.

Step 7: Supportive ICU measures. Place the patient in a dark, quiet room to minimize sensory stimulation that triggers spasms. Nutritional support via enteral feeding (or parenteral if necessary) is essential given the prolonged course. DVT prophylaxis, stress ulcer prophylaxis, and prevention of pressure injuries are standard ICU care components.

05Post-Exposure Prophylaxis (PEP) Algorithm

This is one of the most commonly tested concepts related to tetanus. The PEP algorithm stratifies patients by two variables: wound type and vaccination history.

Wound Classification

PEP Decision Table

First, classify the wound. This is the branching point. A wound is classified as tetanus-prone if it meets any of the following criteria: contaminated with dirt, soil, feces, or saliva; puncture wounds (the classic "rusty nail"); crush injuries; burns; frostbite; wounds with devitalized or necrotic tissue; and wounds that are more than 6 hours old before treatment. All other wounds are considered clean and minor.

Second, determine the vaccination history. This requires asking: "How many doses of tetanus toxoid has this patient received in their lifetime?" The three critical thresholds are:

• Unknown or fewer than 3 lifetime doses: The patient has no reliable immunity. For clean wounds, give Td/Tdap vaccine to begin building active immunity, but TIG is unnecessary because the wound carries low risk. For tetanus-prone wounds, give both Td/Tdap and TIG because the patient has no protective antibodies and the wound is high-risk. This is the only scenario in which TIG is indicated for prophylaxis (as opposed to treatment of established disease). The prophylactic TIG dose is 250 IU IM (much lower than the therapeutic dose of 3,000-6,000 IU).

• Three or more doses, with the last dose less than 5 years ago: The patient is considered fully protected. Neither vaccine booster nor TIG is needed regardless of wound type.

• Three or more doses, with the last dose 5 to 10 years ago: For clean, minor wounds, immunity is considered adequate and no intervention is needed. For tetanus-prone wounds, administer a Td/Tdap booster to ensure protective antibody levels are maintained. TIG is not needed because the patient already has an established immune memory that can be rapidly recalled with a booster.

• Three or more doses, with the last dose 10 or more years ago: Waning immunity is now a concern regardless of wound type. Administer a Td/Tdap booster for both clean and tetanus-prone wounds. TIG is still unnecessary because the immune memory exists; it simply needs a recall stimulus from the booster.

Third, choose between Td and Tdap. In adults who have never received Tdap, the preferred product is Tdap (which includes acellular pertussis coverage). If the patient has already received Tdap previously, use Td for the booster. In patients aged 11 years or older who have never received Tdap, one dose of the primary series or booster should be Tdap.

Fourth, if TIG and Td/Tdap are both indicated, administer them simultaneously but at different anatomical sites using separate syringes. This prevents the immune globulin from neutralizing the vaccine antigen before the immune system can mount a response.

Neonatal Tetanus Prevention

Neonatal tetanus prophylaxis relies on maternal vaccination. Pregnant women should receive Tdap during each pregnancy, ideally between 27 and 36 weeks of gestation, to allow transplacental transfer of antibodies to the fetus. This is particularly relevant in low-resource settings where unsterile umbilical cord practices are common.

06Differential Diagnosis and Distractors

07Traps and High-Yield Pearls

The most common trap on this topic is the post-exposure prophylaxis algorithm. Vignettes will present a patient with a wound and ask what the "next best step" is. Students frequently make errors in two directions: over-treating clean, minor wounds in fully vaccinated individuals (giving unnecessary TIG), or under-treating tetanus-prone wounds in patients with unknown or incomplete vaccination (forgetting to add TIG alongside the vaccine). The critical rule to internalize is that TIG is only indicated prophylactically when the patient has fewer than three documented vaccine doses AND the wound is tetanus-prone. In every other scenario, the booster alone (or nothing at all) is sufficient.

A second common mistake involves the choice of antibiotic. Students reflexively select penicillin because C. tetani is susceptible. However, metronidazole is preferred because penicillin acts as a GABA antagonist and could theoretically worsen the disinhibition that drives tetanus pathology. This pharmacologic reasoning is a favorite testing point.

Third, students forget that tetanus does not confer natural immunity. This is counterintuitive because most infections generate lasting immunity. The sublethal amount of toxin that causes disease is insufficient to provoke a protective antibody response. Therefore, every patient recovering from tetanus must complete the full vaccination series as if they were never exposed.

Fourth, be alert to the conscious patient with severe spasms. Unlike seizures, meningitis, or encephalitis, patients with tetanus maintain a clear sensorium throughout. If a vignette describes a patient with muscle rigidity and spasms who is awake, alert, and oriented, tetanus should rise to the top of your differential. Loss of consciousness should redirect you toward alternative diagnoses.

Finally, in neonatal tetanus vignettes, the setup typically describes a newborn (day 3 to 14 of life) in a resource-limited setting with an unvaccinated mother, poor feeding, rigidity, and spasms following an unsterile umbilical cord practice. The core competency being tested here is the link between maternal vaccination failure and neonatal disease, reinforcing that prevention through Tdap during pregnancy is the most impactful intervention.